NCT05457049Recruiting
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Dynamic Observational Strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients After Complete Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 180 (estimated)
- First submitted
- 9 Jul 2022
- Start date
- 1 Aug 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Guangdong Association of Clinical Trials
- Diseases
- Lung cancer
- NCT number
- NCT05457049
What you commit to
- Study type: Observational
- Planned participants: 180
- From 1 Aug 2022 to the primary completion date, 31 Dec 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.
Other illness
- Patients with a history of other malignancies in the past 5 years.
- Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).
Who the study is looking for
- Stage IB-IIIA non-small cell cancer patients who after complete resection.
- ≥18 years.
- Two-round MRD tests confirm landmark undetectable MRD.
- Expected survival ≥12 weeks.
- Expected survival ≥12 weeks.
- ECOG PS 1-2.
- Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First People's Hospital of Foshan Coordinator of this site? Confirm its status | Foshan | China | Recruiting |
| Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
| the First Affiliated Hospital of Shantou University Medical College Coordinator of this site? Confirm its status | Shantou | China | Recruiting |
| Shantou Centeral Hospital Coordinator of this site? Confirm its status | Shantou | China | Recruiting |
| Zhongshan City People's Hospital Coordinator of this site? Confirm its status | Zhongshan | China | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.